<DOC>
	<DOCNO>NCT00003215</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining peripheral stem cell transplantation one drug regimen may kill tumor cell . It know whether receive standard combination chemotherapy alone effective receive multiple combination chemotherapy plus peripheral stem cell transplantation aggressive non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial compare give different combination chemotherapy regimens together peripheral stem cell transplantation see well work treat patient newly diagnose aggressive non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy sequential high-dose chemotherapy autologous peripheral blood stem cell transplantation standard chemotherapy ( cyclophosphamide , doxorubicin , vincristine , prednisone ) patient newly diagnose aggressive non-Hodgkin 's lymphoma poor prognostic factor . - Compare toxic effect 2 regimen patient . - Compare response rate overall survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . - Arm I : Patients receive standard chemotherapy comprise cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) . Patients receive cyclophosphamide IV 30 minute , doxorubicin IV , vincristine IV day 1 . Patients receive oral prednisone daily day 1-5 . Treatment repeat every 21 day 6-8 course . Patients bulky disease diagnosis residual disease chemotherapy receive radiotherapy 30-60 day initiation last course CHOP . - Arm II : Patients receive 5 regimen chemotherapy administer sequence . - Regimen A : Patients receive CHOP Arm I . - Regimen B : Three week start regimen A , patient receive high-dose cyclophosphamide IV 24 hour day 1 . Patients without initial bone marrow involvement receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 3 continue autologous peripheral blood stem cell ( PBSC ) harvest . PBSC harvest day 13-15 blood count recover . Patients initial bone marrow involvement undergo harvest PBSC time , receive G-CSF SC daily . - Regimen C : Two three week high-dose cyclophosphamide , patient receive vincristine IV high-dose methotrexate IV 6 hour day 2 . Patients receive leucovorin calcium IV every 6 hour day 3-5 begin 24 hour initiation methotrexate infusion . - Regimen D : Within 1-2 week administration methotrexate regimen C , patient receive methylprednisolone IV follow 6 hour later high-dose etoposide IV 10 hour day 1 . Patients receive methylprednisolone IV day 2 . Patients without initial bone marrow involvement receive G-CSF SC daily begin day 3 continue blood count recover . Patients initial bone marrow involvement receive G-CSF SC daily autologous PBSC harvest . PBSC harvest day 10-14 blood count recover . - Regimen E : Myeloablative therapy autologous PBSC transplantation begin 16-40 day administration etoposide . Patients receive mitoxantrone IV 1 hour every 2 hour 3 dos day 2 melphalan IV 30 minute day 5 . PBSC reinfused day 6 begin least 24 hour administration melphalan . Patients receive G-CSF SC continuous infusion begin day 7 . Patients bulky disease diagnosis residual disease chemotherapy receive radiotherapy 30-100 day PBSC transplantation . Patients high risk develop CNS disease receive prophylactic intrathecal chemotherapy . Patients may receive cytarabine , methotrexate , hydrocortisone methotrexate hydrocortisone every 1-2 week 6 course . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 400 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma ( NHL ) Diffuse large Bcell lymphoma Primary mediastinal large Bcell lymphoma Anaplastic large cell lymphoma ( Bcell , Tcell , nullcell type ) At least two follow risk factor : Stage III IV LDH great upper limit normal ( ULN ) ECOG 2 , 3 , 4 No CNS involvement PATIENT CHARACTERISTICS : Age : 18 60 Performance status : See Disease Characteristics ECOG 04 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No hepatitis B C AST ALT great 2 time ULN* Bilirubin great 2.34 mg/dL* NOTE : *Unless due tumor involvement Renal : Creatinine clearance least 60 mL/min ( unless due tumor involvement ) Cardiovascular : No significant heart failure LVEF normal No active angina pectoris No myocardial infarction within past 6 month No major ventricular arrhythmia Pulmonary : No significant lung disorder Other : HIV negative No severe active acute chronic infection No severe psychoses No prior concurrent malignancy except adequately treat carcinoma situ cervix nonmelanomatous skin cancer Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy NHL ( except emergency therapy , 1 course standard chemotherapy ) Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy NHL ( except emergency therapy great 600 cGy radiation ) No concurrent prophylactic radiotherapy brain Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>